Heritage Family Offices LLP Has $2.17 Million Stock Position in Stryker Co. (NYSE:SYK)

Heritage Family Offices LLP increased its stake in shares of Stryker Co. (NYSE:SYK) by 7.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,027 shares of the medical technology company’s stock after acquiring an additional 429 shares during the quarter. Stryker comprises approximately 1.1% of Heritage Family Offices LLP’s holdings, making the stock its 17th largest holding. Heritage Family Offices LLP’s holdings in Stryker were worth $2,170,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Winch Advisory Services LLC grew its position in Stryker by 0.3% in the 4th quarter. Winch Advisory Services LLC now owns 14,732 shares of the medical technology company’s stock worth $5,304,000 after purchasing an additional 39 shares during the last quarter. ERn Financial LLC grew its position in Stryker by 2.4% during the fourth quarter. ERn Financial LLC now owns 3,984 shares of the medical technology company’s stock worth $1,434,000 after buying an additional 94 shares in the last quarter. HCR Wealth Advisors increased its stake in Stryker by 2.9% during the fourth quarter. HCR Wealth Advisors now owns 7,626 shares of the medical technology company’s stock valued at $2,746,000 after acquiring an additional 214 shares during the period. Thurston Springer Miller Herd & Titak Inc. raised its holdings in Stryker by 50.1% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 8,733 shares of the medical technology company’s stock valued at $3,145,000 after acquiring an additional 2,914 shares in the last quarter. Finally, Park Avenue Securities LLC lifted its position in shares of Stryker by 25.3% in the 4th quarter. Park Avenue Securities LLC now owns 10,613 shares of the medical technology company’s stock worth $3,821,000 after acquiring an additional 2,142 shares during the period. 77.09% of the stock is owned by institutional investors.

Stryker Stock Up 1.5 %

Shares of NYSE:SYK opened at $368.09 on Thursday. Stryker Co. has a 12 month low of $307.23 and a 12 month high of $398.20. The firm has a market cap of $140.32 billion, a P/E ratio of 39.45, a P/E/G ratio of 2.51 and a beta of 0.95. The company has a quick ratio of 1.22, a current ratio of 1.91 and a debt-to-equity ratio of 0.66. The company’s 50-day moving average price is $375.13 and its two-hundred day moving average price is $358.25.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.10. The business had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. Stryker’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the business posted $2.46 earnings per share. As a group, research analysts forecast that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be issued a $0.84 dividend. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a yield of 0.91%. Stryker’s dividend payout ratio (DPR) is currently 36.01%.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Robert W. Baird boosted their price objective on Stryker from $378.00 to $405.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Tuesday, January 7th. Canaccord Genuity Group increased their price objective on shares of Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Citigroup lifted their target price on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Finally, Piper Sandler reissued an “overweight” rating and issued a $420.00 price target (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average target price of $405.80.

Insiders Place Their Bets

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at approximately $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.